Solidus Labs Unveils HALO: A Crypto-Native Market Integrity Hub Tailored for Digital Assets
23.3.2022 16:00:00 EET | Business Wire | Press release
Solidus Labs, the category-definer for crypto-native market integrity solutions, announced today the launch of HALO, the first automated, comprehensive and testable trade surveillance and market integrity hub tailored for digital assets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005138/en/
Halo by Solidus Labs (Photo: Business Wire)
HALO’s launch will be instrumental in shaping the future of financial risk monitoring. Built from the ground up to bridge the gap between crypto and traditional finance, HALO provides Wall-Street grade crypto-native regulatory risk and compliance solutions. Increasingly, financial institutions are relying on HALO as they expand into new revenue opportunities offered by digital assets. Beyond a growing client-base of crypto and DeFi businesses, HALO is also set to offer government agencies tools to create transparency, enable innovative regulatory frameworks and ensure safe and regulated crypto financial services in their jurisdictions. The platform addresses numerous crypto-specific challenges, like new market structures, volatility, volumes, data types, decentralized services, trading dynamics, crypto-native market abuse typologies - and evolving business and regulatory demands.
“Crypto’s potential to make financial services more accessible, transparent, liquid and efficient, depends on state-of-the-art financial risk monitoring that enables the merits of digital assets, while surgically mitigating its many new risks,” said Asaf Meir, Founder and CEO of Solidus Labs. “HALO does that by unifying formerly disparate risk data points, and continually monitoring that data in real-time, creating a behavioral-based universal client risk profile that allows our clients to focus on real risk, in real-time, throughout the investment journey.”
Combining cutting edge machine learning technology and decades of traditional financial risk know-how and best practices, HALO is uniquely tailored to address the “triple T” (T3) pillars of market integrity in the crypto and DeFi space - trade surveillance, transaction monitoring, and threat intelligence. HALO’s modules include:
Trade Surveillance: HALO’s comprehensive market surveillance tools ensure market integrity by benchmarking abnormal crypto orders and execution patterns against the market norm, to alert businesses and networks on potential breaches of trading rules or unusual market volatility. HALO users can easily customize detection model sensitivity and backtest against real data in order to meet the needs of quickly evolving regulatory and compliance landscapes.
Transaction monitoring: HALO’s continuous real-time monitoring of crypto and fiat transactions offers unprecedented blockchain-native capabilities and enables detecting, investigating and reporting suspicious crypto deposits and withdrawals for anti-money laundering (AML), sanctions, and financial risk compliance.
Threat Intelligence: Relying on a built-in onboarding verification tool, powerful integrations and crypto-native infrastructure, HALO’s Universal Client Risk Profile aggregates risk across the entire investment journey and multiple markets - from onboarding to trading, post-trade and everything in between. Synthesizing numerous signals into a single threat intelligence hub, HALO surgically surfaces overlooked threats in crypto and DeFi services, enabling businesses to act upon them in real time.
HALO currently protects more than 25 million retail and institutional investors globally, and is actively used to monitor over one trillion events per day. The platform deploys over 50 different proprietary market abuse typologies, shielding investors and safeguarding crypto businesses from new threats unique to the crypto and decentralized finance space. “Since our founding, our deepest commitment has been to enable a safer crypto ecosystem. HALO brings us one step closer to that goal while taking user experience to the next level, empowering risk and compliance teams and allowing crypto businesses to grow safer,” Meir said. “It’s a culmination of thousands of hours of work with crypto teams and discussions with regulators, fulfilling our vision of harnessing crypto not only as an opportunity to transform financial services, but also as an opportunity to take financial risk monitoring into the future.”
To learn more about Solidus Labs and HALO visit: www.soliduslabs.com
About Solidus Labs:
Solidus Labs is the category-definer for crypto-native triple T (T3) market integrity solutions - trade surveillance, transaction monitoring, and threat intelligence.
Our mission is to enable safer crypto trading throughout the investment journey across all centralized and DeFi markets. As the founder of industry leading initiatives like the Crypto Market Integrity Coalition and DACOM Summit, and in everything we do, Solidus is deeply committed to ushering in the financial markets of tomorrow.
Crypto exchanges, financial institutions and regulators globally rely on Solidus HALO - our real time, comprehensive, testable, and future-proof platform. Safeguarding their business from known forms of market abuse and a plethora of emerging crypto-specific risks, we enable our clients to grow faster - and safer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005138/en/
Contact information
Media
Trevor Davis, Gregory FCA
P: 443-248-0359
E: trevor@gregoryfca.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
